公开(公告)号：US20240269149A1

公开(公告)日：2024-08-15

申请号：US18454012

申请日：2023-08-22

Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION ,  THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS

Inventor： Christopher M. ADAMS ,  Steven D. KUNKEL ,  Michael WELSH

IPC: A61K31/58 ,  A61K31/215 ,  A61K31/352 ,  A61K31/353 ,  A61K31/36 ,  A61K31/382 ,  A61K31/404 ,  A61K31/407 ,  A61K31/4164 ,  A61K31/4166 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/436 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/438 ,  A61K31/4706 ,  A61K31/473 ,  A61K31/56 ,  A61K31/565 ,  C12Q1/6809 ,  G01N33/50

CPC classification number: A61K31/58 ,  A61K31/215 ,  A61K31/352 ,  A61K31/353 ,  A61K31/36 ,  A61K31/382 ,  A61K31/404 ,  A61K31/407 ,  A61K31/4164 ,  A61K31/4166 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/436 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/438 ,  A61K31/4706 ,  A61K31/473 ,  A61K31/56 ,  A61K31/565 ,  C12Q1/6809 ,  G01N33/5023 ,  C12Q2600/136 ,  G01N2800/10 ,  G01N2800/52

Abstract: The invention provides a method for (a) increasing skeletal muscle mass; (b) reducing skeletal muscle atrophy; (c) increasing muscular strength; (d) promoting muscle growth; (e) decreasing muscle wasting; or (f) increasing strength per unit of muscle mass in an animal identified or having been identified to be in need of one or more of (a)-(f), the method comprising administering to the animal an effective amount of a compound of formula:




or a stereoisomer, solvate, or pharmaceutically acceptable salt thereof, thereby accomplishing one or more of (a)-(f).

公开(公告)号：US20230349921A1

公开(公告)日：2023-11-02

申请号：US18173604

申请日：2023-02-23

Applicant: Shriners Hospitals for Children

Inventor： William A. Horton ,  Gregory P. Lunstrum ,  Ryan F. Coghlan ,  Jon A. Oberdorf

IPC: G01N33/68 ,  G01N33/50 ,  G01N33/543 ,  G01N33/566 ,  C07K14/78 ,  G01N33/535 ,  G01N33/574

CPC classification number: G01N33/6887 ,  C07K14/78 ,  G01N33/5029 ,  G01N33/5044 ,  G01N33/5082 ,  G01N33/535 ,  G01N33/54306 ,  G01N33/566 ,  G01N33/57488 ,  A61K38/00 ,  G01N2800/10 ,  G01N2800/52 ,  G01N2800/60

Abstract: The present invention provides methods for determining bone growth velocity comprising: (a) measuring an amount of a collagen X marker in a sample obtained from a subject in need thereof; and (b) comparing the amount of collagen X marker measured in step (a) with a collagen X marker standard curve, wherein the amount of collagen X marker is measured using at least two reagents. In an embodiment, there is at least one capture reagent and at least one detection reagent. In a preferred embodiment for measuring CXM, the capture reagent is the aptamer SOMA1 and the detection reagent is the monoclonal antibody mAb X34. The present invention further provides methods for treating diseases, disorders or conditions comprising receiving an identification of an amount of CXM in a sample, wherein the amount of CXM has been identified using a combination of SOMA1 and mAb X34 as CXM-binding reagents, and administering a treatment in light of the amount of CXM in the sample.

公开(公告)号：US11802873B2

公开(公告)日：2023-10-31

申请号：US16618118

申请日：2018-05-29

Applicant: CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN

Inventor： Simon Reinke ,  Sven Geissler ,  Georg Duda ,  Hans-Dieter Volk ,  Michael Fuchs ,  Katharina Schmidt-Bleek ,  Patrick Strube ,  Matthias Pumberger

IPC: G01N33/53 ,  G01N33/569 ,  C07K14/51 ,  A61K49/00 ,  A61K38/00

CPC classification number: G01N33/56972 ,  A61K49/0004 ,  C07K14/51 ,  A61K38/00 ,  G01N2333/70517 ,  G01N2333/70521 ,  G01N2333/70596 ,  G01N2800/10 ,  G01N2800/52

Abstract: Provided herein is a method for predicting the probability of having or developing a non-fusion, wherein said method comprises determining the frequency of a subpopulation of CD8+ T cells selected from CD8+CD57+, CD8+CD28− and CD8+CD57+CD28− in a sample obtained from a patient. Also provided herein is a system for predicting the probability of having or developing a non-fusion.

公开(公告)号：US20180267062A1

公开(公告)日：2018-09-20

申请号：US15986326

申请日：2018-05-22

Applicant: ESM TECHNOLOGIES, LLC

Inventor： Kevin J. Ruff

IPC: G01N33/68 ,  A61K35/57

CPC classification number: G01N33/6887 ,  A61K35/57 ,  G01N2333/78 ,  G01N2800/10 ,  G01N2800/52

Abstract: The invention provides a method for determining the efficacy of compositions used to treat articular joint conditions in mammals. The method includes measuring the change in levels of one or more cartilage degradation biomarkers in a mammal from before exercise and after exercise, then administering a composition used to treat articular joint conditions to the mammal, and measuring the change in levels of one or more cartilage degradation biomarkers in the mammal from before exercise and after exercise.

公开(公告)号：US20180171015A1

公开(公告)日：2018-06-21

申请号：US15878538

申请日：2018-01-24

Applicant: CHU SAINTE-JUSTINE

Inventor： Alain Moreau ,  Marie-Yvonne Akoume Ndong

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/24 ,  G01N33/74 ,  C12Q1/6883 ,  A61K31/713

CPC classification number: C07K16/2839 ,  A61K31/713 ,  A61K39/3955 ,  C07K16/24 ,  C07K16/2884 ,  C07K2317/76 ,  C12Q1/6883 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/172 ,  G01N33/74 ,  G01N2333/70585 ,  G01N2800/10 ,  G01N2800/50

Abstract: Disclosed herein are methods of determining the risk of developing a scoliosis based on the presence of at least one copy of a CD44 risk allele; methods of stratifying a subject having a scoliosis; methods of treating subjects having a scoliosis and compositions and kits for performing these methods.

公开(公告)号：US09983214B2

公开(公告)日：2018-05-29

申请号：US15130120

申请日：2016-04-15

Applicant: ESM TECHNOLOGIES, LLC

Inventor： Kevin J. Ruff

IPC: G01N33/53 ,  G01N33/68 ,  A61K35/57

CPC classification number: G01N33/6887 ,  A61K35/57 ,  G01N2333/78 ,  G01N2800/10 ,  G01N2800/52

Abstract: The invention provides a method for determining the efficacy of compositions used to treat articular joint conditions in mammals. The method includes measuring the change in levels of one or more cartilage degradation biomarkers in a mammal from before exercise and after exercise, then administering a composition used to treat articular joint conditions to the mammal, and measuring the change in levels of one or more cartilage degradation biomarkers in the mammal from before exercise and after exercise.

公开(公告)号：US09778250B2

公开(公告)日：2017-10-03

申请号：US14116540

申请日：2012-05-10

Applicant: Steven A. Greenberg ,  Mohammad K. Salajegheh

Inventor： Steven A. Greenberg ,  Mohammad K. Salajegheh

IPC: G01N33/543 ,  G01N33/564 ,  C12N9/16

CPC classification number: G01N33/54306 ,  C07K2319/00 ,  C07K2319/21 ,  C07K2319/23 ,  C07K2319/43 ,  C12N9/16 ,  G01N33/564 ,  G01N2333/46 ,  G01N2800/10 ,  G01N2800/52

Abstract: Methods, devices, kits and systems for diagnosing inclusion body myositis (IBM) are provided. Methods, devices, kits and systems involves detecting the presence and/or level of autoantibodies that are reactive against at least a ˜43 kilodalton (kDa) protein or ˜43 kDa protein band from a muscle lysate or a mammalian cell lysate, or autoantibodies that are reactive against a cytosolic 5′-nucleotidase 1A protein (NT5C1A), or a cytosolic 5′-nucleotidase 1B protein (NT5C1B), or a NT5C1B isoform thereof, or a peptide fragment thereof, an isolated peptide thereof or a fusion protein comprising an isolated peptide of NT5C1A or NT5C1B. Such autoantibodies are only found in IBM patients and not in patients with other myopathies.

公开(公告)号：US20170267782A1

公开(公告)日：2017-09-21

申请号：US15505762

申请日：2015-08-07

Applicant: NITTO BOSEKI CO., LTD.

Inventor： Wataru KIKUCHI ,  Kumiko SASAGAWA ,  Kenta NODA

IPC: C07K16/40 ,  G01N33/573

CPC classification number: C07K16/40 ,  A61K38/00 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/30 ,  C07K2317/14 ,  C07K2317/33 ,  C12N5/12 ,  C12N5/163 ,  C12N9/16 ,  C12N15/00 ,  C12N15/02 ,  C12Y301/03002 ,  G01N33/5008 ,  G01N33/53 ,  G01N33/543 ,  G01N33/545 ,  G01N33/553 ,  G01N33/573 ,  G01N33/577 ,  G01N2333/916 ,  G01N2800/10

Abstract: The purpose of the present invention is to provide a monoclonal antibody that is useful in specifically assaying tartrate resistant acid phosphatase 5b (TRACP-5b). A hybridoma producing a monoclonal antibody against TRACP-5b, said monoclonal antibody showing higher reactivity with TRACP-5b than with tartrate resistant acid phosphatase 5a (TRACP-5a) and, therefore, being specific to TRACP-5b, is obtained by cell fusion using, as an antigen, human recombinant TRACP-5b purified from silkworm silk gland. By using this monoclonal antibody, TRACP-5b in a specimen can be highly sensitively and specifically detected.

公开(公告)号：US20170096457A1

公开(公告)日：2017-04-06

申请号：US15311667

申请日：2015-05-15

Applicant: University of Oregon

Inventor： Karen Guillemin ,  Annah Rolig

IPC: C07K14/195 ,  A61K45/06 ,  A61K38/16

CPC classification number: C07K14/195 ,  A61K38/00 ,  A61K38/164 ,  A61K45/06 ,  G01N33/5088 ,  G01N2333/4603 ,  G01N2800/10 ,  G01N2800/102 ,  G01N2800/7095 ,  Y02A50/473

Abstract: Disclosed herein are methods of treating or inhibiting inflammation in a subject by administering an anti-inflammatory protein to the subject. In some embodiments, the protein has at least 80% sequence identity to the amino acid sequence set forth as SEQ ID NO: 1 or fragments thereof. Also disclosed are methods of identifying anti-inflammatory compounds by determining the effect of test compounds on inflammation in zebrafish gut. In some embodiments, germ-free zebrafish or zebrafish inoculated with a single defined bacterial strain are contacted with one or more test compounds and a marker of inflammation in the gut is measured and compared to a control. Recombinant vectors including a nucleic acid encoding the anti-inflammatory protein (such as a nucleic acid encoding a protein with at least 80% sequence identity to SEQ ID NO: 1 or fragments thereof) operably linked to a heterologous promoter are also disclosed.

公开(公告)号：US09511115B2

公开(公告)日：2016-12-06

申请号：US12897397

申请日：2010-10-04

Applicant: Chia Soo ,  Kang Ting ,  Shunichi Kuroda ,  Ben Wu

Inventor： Chia Soo ,  Kang Ting ,  Shunichi Kuroda ,  Ben Wu

IPC: C07K14/51 ,  A61K35/32 ,  A61K38/17 ,  A61L27/22

CPC classification number: A61K38/1709 ,  A61K31/728 ,  A61K35/32 ,  A61L27/22 ,  A61L27/227 ,  G01N2800/10 ,  Y10T436/143333

Abstract: Provided herein is a pharmaceutical composition for treating, preventing or ameliorating a bone or cartilage condition and methods of making and using the same.

Abstract translation: 本文提供了用于治疗，预防或改善骨或软骨病症的药物组合物及其制备和使用方法。